In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Abstract Text:

Klaudia Kosowska-Shick,Catherine Clark,Kim Credito,Bonifacio Dewasse,Linda Beachel,Lois Ednie,Peter C Appelbaum,Klaudia Kosowska-Shick,Catherine Clark,Kim Credito,Bonifacio Dewasse,Linda Beachel,Lois Ednie,Peter C Appelbaum,

When tested against nine strains of pneumococci and six of Haemophilus influenzae of various resistotypes, faropenem failed to select for resistant mutants after 50 days of consecutive subculture in subinhibitory concentrations. Faropenem also yielded low rates of spontaneous mutations against all organisms of both species. By comparison, resistant clones were obtained with macrolides, ketolides, and quinolones.

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Publishing Authors By Initials

K Kosowska-Shick,C Clark,K Credito,B Dewasse,L Beachel,L Ednie,PC Appelbaum,K Kosowska-Shick,C Clark,K Credito,B Dewasse,L Beachel,L Ednie,PC Appelbaum,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Antimicrobial agents and chemotherapy

VOLUME: 52

Page Numbers: 748-52

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 17

MONTH: 12

YEAR: 2007

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.

AFFILIATION: Department of Pathology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033. pappelbaum@psu.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae Related Publications

• A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects.
• Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
• Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
• Agnogenic myeloid metaplasia: a case report.
• Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
• Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
• Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
• Coherent Spin Transport through a 350 Micron Thick Silicon Wafer.
• Commentary: the use of restraint and seclusion in correctional mental health.
• Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis.
• Development of autonomy: role of walking onset and its timing.
• Disclosure of information to potential subjects on research recruitment web sites.
• Ethics and forensic psychiatry: translating principles into practice.
• Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
• Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow.
• Hormone receptors in breast cancer.
• Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
• In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci.
• In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.
• Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
• Law & psychiatry: Death row delusions: when is a prisoner competent to be executed?
• Law & psychiatry: privilege in the federal courts: should there be a "dangerous patient exception"?
• Law & psychiatry: sex offenders in the community: are current approaches counterproductive?
• Molecular characterization of multidrug-resistant Streptococcus pneumoniae isolates in Korea. The Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group.
• Patients' competence to consent to treatment.
• Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).
• Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
• Retrolental fibroplasia; a disease of the eyes in premature infant; with report of a case.
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
• The voluntary patient--a psychiatrist's perspective.